ARLINGTON, VA, March 10, 2026 (EZ Newswire) -- The Health Management Academy (THMA), a membership-based executive healthcare community founded in 1998, announced its 2026 Cardiovascular and Oncology Forums will take place May 6–8, 2026, in Fort Lauderdale, Florida. These forums are invitation-only conferences that will bring together chief executives and senior strategy leaders from major U.S. health systems and life sciences organizations to address the convergence of technology adoption, value-based care transformation, and pharmaceutical market evolution.
The announcement reflects growing demand among life sciences companies for structured access to health-system decision-makers at a moment when the commercial and clinical environments are shifting in tandem. A Deloitte 2026 outlook survey found that 43% of C-suite healthcare executives describe themselves as uncertain or neutral about the near-term market, and that 80% expect regulatory factors to significantly influence their strategic planning. The digital health technology sector is projected to exceed $300 billion in market value in 2026, driven by AI-powered clinical decision support and ambient documentation tools. Concurrently, GLP-1 therapies are being positioned by health systems and manufacturers as long-term investments in chronic disease management rather than short-cycle pharmaceutical products, raising consequential questions about reimbursement strategy, patient selection, and commercial distribution.
THMA's 2026 Cardiovascular and Oncology Executive Convenings will address the strategic, operational, and commercial dimensions of these developments through peer-led discussion among senior executives from health systems and industry organizations. Forum sessions will examine how health systems are evaluating AI adoption in clinical and administrative functions, how GLP-1 and cardiometabolic therapies are being integrated into population health and value-based programs, how manufacturers and health systems are renegotiating partnership and contracting models under alternative payment frameworks, and how data interoperability and technology infrastructure decisions are being made at the board and executive committee level.
What THMA Member Data Reveals
THMA's community of more than 2,000 health-system executive relationships and approximately 600 C-suite members provides a continuous signal on the priorities and concerns of the organizations that life sciences companies most need to understand. Across THMA's previous forum activity and its quarterly executive trend readouts, several consistent themes have emerged that will anchor the 2026 Cardiovascular and Oncology program design.